OPPM
NTLA icon

Opus Point Partners Management’s Intellia Therapeutics NTLA Stock Holding History

Opus Point Partners Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$380K Hold
28,490
– – 0.69% 37
2019
Q2 		$466K Hold
28,490
– – 0.69% 38
2019
Q1 		$487K Buy
+28,490
New +$425K 0.66% 36

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Opus Point Partners Management's NTLA Position: Q3 2019 in Review

Opus Point Partners Management held its Intellia Therapeutics (NTLA) position steady in Q3 2019 at 28,490 shares worth $380K. The position accounts for 0.69% of the portfolio, ranked #37.

Opus Point Partners Management first reported a position in NTLA in Q1 2019 and has held it in 3 quarters since. The position peaked at $487K in Q1 2019. 136 funds tracked by Wall St. Rank hold NTLA as of Q3 2019.

  • Opus Point Partners Management held 28,490 shares of Intellia Therapeutics worth $380K as of Q3 2019.
  • Opus Point Partners Management left its Intellia Therapeutics share count unchanged in Q3 2019.
  • Intellia Therapeutics made up 0.69% of Opus Point Partners Management's portfolio in Q3 2019, its #37 holding.
  • Opus Point Partners Management first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Opus Point Partners Management's Intellia Therapeutics position peaked at $487K in Q1 2019.
  • 136 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.